A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Roy S. Herbst, Alfonso Gurpide, Veerle Surmont, Dong-Wan Kim, Saiama Naheed Waqar, Judith Herder, Dae Ho Lee, Enric Carcereny, Noemi Reguart, John M. Wallmark, Suresh S. Ramalingam, Corey J. Langer, Gregory M. Lubiniecki, James Knowles, Honghong Zhou, Mary Elizabeth Hanson, Paul Baas
Institutions: Yale University, Clinica Universidad de Navarra, Ghent University Hospital, Seoul National University Hospital, Washington University in St. Louis, St. Antonius Ziekenhuis, Asan Medical Center, University of Ulsan, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Hospital Clínic de Barcelona, Emory University, Winship Cancer Institute, Abramson Cancer Center, University of Pennsylvania, Merck & Co., Inc., Rahway, NJ, USA (United States), The Netherlands Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2418482327